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1 Introduction
The respiratory distress syndrome (RDS) con-
tinues to rank as a major cause of mortality
among non-malformed infants. Even when it is
not fatal, the disease may have late sequelae,
involving mainly the central nervous system
(CNS) and the cardiopulmonary apparatus.
The incidence of RDS is inversely correlated
with gestational age. Its cause is the insufficient
production of substances that lower surface
tension (surfactants) in fetal lungs.
The experience of LIGGINS and HOWIE [7] with
antenatal maternal administration of steroids
for prevention of RDS led to widespread adop-
tion of this preventive approach. Further stud-
ies substantially confirmed the effectiveness of
the steroids but also brought to light several
conditions in which the benefit was slight or nil
[1, 2, 4, 11].
These conditions include: 1) treatment to deliv-
ery time less than 24 hours and more than one
week, 2) gestational age less than 30 and more
than 34 weeks, 3) rupture of membranes (ROM)
more than 48 hours prior to delivery, 4) male
sex, 5) white race, 6) multiple pregnancy, and
7) fetal acidosis.
Furthermore steroids have potential maternal,
fetal and neonatal adverse effects [4,16,17,19],
among which the most dangerous is probably
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the increased incidence of neonatal infection,
to which preterm infants are already more sus-
ceptible. The percentage of deaths due to infec-
tion within 28 days of birth was higher and
polymorphonuclear leukocytes (PMNL)
functions were reduced in infants whose
mothers had received steroids for prevention of
RDS than in those whose mothers had not been
treated [5].
All this has encouraged attempts to find al-
ternative treatments of at least equal efficacy
but without adverse reactions. Many substan-
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ces have been held to be capable of stimulating
surfactant production: aminophylline, thyroid
hormones, cyclic-AMP, ethanol, fibroblast-
pneumocyte factor, bromhexine and others.
None of them — for various reasons — has
been accepted as a true alternative to steroids.
A series of experimental data have demon-
strated that ambroxol, a benzylamine, stimula-
tes surfactant production and secretion by type
II pneumocytes, even though the mechanism of
action is not yet fully understood.
The most important experimental findings are
that ambroxol:
1) increases surfactant phospholipids concen-
trations in the amniotic and fetal tracheal
fluid [3, 10];
2) stimulates the development of intracellular
organelles involved in the surfactant secre-
tion process [18];
3) increases pulmonary compliance in the rab-
bit neonate [12]. Ambroxol readily crossess
the placental barrier and concentrates elec-
tively in the fetal lungs and liver [13];
4) and it has been demonstrated that am-
broxol lowers the incidence of RDS in pre-
term infants born of treated mothers com-
pared to mothers given placebo [8, 20].
The aim of this study was to evaluate the effec-
tiveness of ambroxol versus the steroids in re-
ducing the incidence of RDS in preterm new-
borns with particular regard to the occurrence
of neonatal infection.
2 Materials and methods
Starting in September 1981, we organized a
randomized multicenter trial in which four
centers in the Lombardy region and two centers
in other regions took part.
Women at 27 to 34 weeks' gestation with
threatened premature or planned premature la-
bor were admitted into the trial.
Criteria for exclusion were:
1) Delivery expected within 24 hours;
2) More than two weeks disagreement in as-
sessing gestational age using patient's his-
tory data and ultrasound data;
3) Severe hypertension (B. P. more than 160/
100 mmHg);
4) Class-B-R diabetes;
5) Hyperthyroidism;
6) Drug addiction with heroin up to the third
trimester of pregnancy;
7) Previous treatment during pregnancy with
drugs enhancing fetal lung maturity.
Tocolysis with a beta-mimetic agent was
allowed to delay labor.
Consenting patients admitted to the trial were
randomly treated, on the basis of chance num-
ber tables, with betamethasone or ambroxol.
The study was stratified with separated rando-
mization for each center and accurate control
was performed on correct use of random tables.
The betamethasone group received 6mg of
betamethasone phosphate and 6 mg of betame-
thasone acetate intramuscularly, and the dose
was repeated 24 hours later. The ambroxol
group received the drug diluted in 500 ml saline
as a slow intravenous infusion according to a
long regimen (1 g/day for 5 days) or a short
regimen (l g every 12 hours for 4 times). The
two ambroxol dosage regimens were chosen
freely in relation to the expected delay of labor.
Because of different route and frequency of
administration of the two drugs a blinded study
was too complicated to be performed.
The diagnosis of RDS was based on the exist-
ence of one or more of both clinical and radio-
logical signs given in table I and its severity was
rated according to the gas-analytical criteria
shown. The diagnosis of maternal puerperal
infection was based upon either the finding of
a skin temperature more than 38 °C on two
occasions (temperatures beeing measured at
least every 6 hours), or a clinical evaluation
consistent with endometritis or wound infec-
tion. The diagnosis of neonatal infection was
based upon clinical and radiological criteria
and confirmed by a positive culture.
Evaluation of maternal and neonatal infection
rate was performed in infants born at each
gestational age only in the four Lombardy re-
gional centers, owing to reasons of organiza-
tion. Neonatal pathology was reviewed in all
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Table I. Criteria for diagnosis of RDS.
RDS defined by the presence of:
Beginning before 4 hours of life
Duration more than 24 hours
Clinical signs (one or more):
Radiological signs:
Respiratory rate >60/min
Intracostal retractions
Flaring of the alae nasi
Grunting on expiration
Cyanosis in room air with falling in PO2 below 60 mmHg
Thoracic roentgenogram showing reticulogranular pattern
and/or air bronchograms
Severity was defined as:
- Mild: if arterial or tcPo2 50-80 mmHg with room FiCh ^ 0.3
- Moderate: if arterial or tcPo2 50-80 mmHg with FiO2 between 0.4. and 0.6. -» c PAP
— Severe: if arterial or tcPo2 mmHg < 50 or Pco2 > 60 with FiO2 between 0.4 and 1 -> assisted ventilation.
cases by a neonatal coinvestigator who was
blinded as to the treatment. All data were
checked and analyzed with an Apple II com-
puter at the IVth Department of Obstetrics
and Gynecology of the University of Milan,
L. Sacco Hospital. Statistical analyses were by
Student's t-test and the chi-square test.
3 Results
As of November 15, 1984, 288 randomized
patients had delivered 315 neonates. Thirty-
eight patients were excluded because of either
the presence of criteria for exclusion or proce-
dural errors. There were 2 stillbirths. Ninety-
nine neonates were born after the 37th week of
pregnancy. 7 died of other causes within the
first 3 hours of life before the onset of RDS
could be established. The incidence of RDS was
assessed in 169 viable neonates born before the
37th completed week of gestation (259 days of
amenorrhea). Of these, 86 were born from 76
mothers treated with betamethasone and 83
from 76 mothers treated with ambroxol (table
II).
All the betamethasone patients completed one
course of treatment, whereas 14 of the am-
broxol group (18%) received less than the
scheduled number of doses because of onset of
labor. Comparison of the mothers in the two
groups showed no significant differences in the
main maternal factors affecting the develop-
ment of RDS (table III). The two groups of
mothers were also compared as to use of beta-
Table Π. Study population.
Groups
Betamethasone
Total randomized
Excluded from the study
Fetal deaths
Liveborn after the 37th week
Early neonatal death before RDS assessment
Mothers
129
21
1
29
2
Infants
144
22
1
33
2
Ambroxol
Mothers
159
15
1
62
5
Infants
171
16
1
66
5
Available for RDS assessment 76 86 76 83
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Table III. Characteristics of treatment groups (mothers)1.
Characteristic Groups
Betamethasone
Gestational age at delivery mean
< 34 weeks (%)
> 34 weeks (%)
Treatment to delivery time mean
ROM to delivery time mean + S
Multiple pregnancy (%)
Cesarean section (%)
Placenta previa (%)
± S. D. (days)
± S. D. (days)
. D. (hours)
(n =
229.0
53
23
14.1
27.3
10
32
4
76)
± 17.2
70%
30%
± 15.9
+ 15.4
13%
42%
5%
Ambroxol
(n =
231.9
52
24
11.4
26.9
7
33
2
76)
+ 13.8
68%
32%
+ 12.9
+ 17.6
9%
43%
3%
1
 Statistical analysis. The difference between the two groups was not significant for any of the recorded characteris-
tics.
mimetic agents, and no significant difference
was found (table IV). There was no significant
difference between the two groups of neonates
as regards main neonatal factors affecting the
development of RDS (table V). The overall
incidence of RDS was higher in the betametha-
sone group (31%) than in the ambroxol group
(13%) as was the incidence of mild, moderate,
severe and fatal RDS. The difference was sig-
nificant (P < 0.05) (table VI).
The incidence of RDS was generally higher in
the betamethasone group vs ambroxol group
in five centers (29% vs 13%, 40% vs 10%, 35%
vs 15%, 29% vs 13%, 24% vs 8%), whereas
in one group it was comparable (13% in the
betamethasone group vs 14% in the ambroxol
group).
The incidence of RDS in neonatal subgroups
divided on the basis of twin births, gestational
age, ROM to delivery time, treatment to deliv-
ery time and sex of the newborn was in every
case higher in the betamethasone group. The
difference was significant in twin births, when
delivery was prior to the 31st week, when ROM
occurred more than 48 hours earlier, and in
female infants. As well as in these conditions,
in which steroids are known not to be effective,
the difference was significant when the treat-
Table IV. Use of betamimetic drugs1.
Betamimetic agents
None
Ritodrine
Isoxsuprine
Salbutamol
More than one drug
Mean total dosage (mg)*
Mean duration of treatment (days)
Betamethasone
(n = 76)
Cases (%)
4
48
11
4
9
494.7
8.3
5
63
14
5
1
+ 639.1
± 8.7
Ambroxol
(n = 76)
Cases (%)
5
50
3
6
12
581.9
8.8
6
66
4
8
16
± 835.9
± 10.9
1
 = Statistical analysis. The difference between the groups was not significant for any of the recorded characteris-
tics.
* = Dosage equalized to ritodrine according to a isoxsuprine/ritodrine dosage ratio of 5:1 and a salbutamol/
ritodrine dosage ratio of 1:10.
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Table V. Characteristics of treatment groups (infants)1
Characteristic
Gestational age mean + S. D. (days)
^ 34 weeks
> 34 weeks
Birth weight mean + S. D. (gm)
< 1.500
> 1.500
Apgar Γ (mean + S.D.)
Apgar 5" (mean + S. D.)
Twins (%)
Groups
Betamethasone
(n = 86)
228.8 + 17.7
60 70%
26 30%
1927 + 540.0
23 27%
63 73%
5.6 + 2.9
7.2 ± 1.9
20 23%
Ambroxol
(n = 83)
232.5 + 13.6
56 68%
27 32%
1982 + 527.0
14 16%
70 84%
5.9 ± 2.6
7.3 ± 2.0
13 17%
= Statistical analysis. The difference between the groups was not significant for any of the recorded characteristics.
Table VI. Incidence of RDS1.
RDS Betamethasone Ambroxol
(n = 86) (n = 83)
Cases (%) Cases (%)
RDS
No RDS
Mild{ ModerateSevereFatal
59
9
7
5
6
69
10
8
6
7
72
7
2
0
2
87
9
2
0
2
1
 = Statistical analysis: X2 = 11,27 (d.f. =4)P < 0.05
ment to delivery interval was between 2 and 7
days, i.e. the limit within which steroids are
effective (table VII).
The incidence of RDS was 15% in neonates
whose mothers had been given the long dosage
regimen and 12% in neonates whose mothers
had been given the short dosage regimen. The
difference was not significant.
The infants born in the four Lombardy regional
centers included 100 in the betamethasone
group and 140 in the ambroxol group. The
puerperal infection rate in the mothers of these
infants was 33% in the betamethasone group
and 36% in the ambroxol group (the difference
was not significant). In the same 240 infants,
the betamethasone group had a slightly lower
gestational age at birth (242 days), a slightly
higher treatment to delivery interval (29.3 days)
and a slightly higher percentage of cases with
ROM >48 hours (24%) than the ambroxol
group (246 days, 28.5 days and 19% respec-
tively). Although none of these differences were
significant, the neonatal infection rate through
the 28th day of life was significantly higher (P
< 0.05) in the betamethasone group (18% with
four fatalities) than in the ambroxol group (9%
with one fatality). The infected neonates in the
betamethasone group had a significantly lower
mean gestational age, significantly shorter
mean treatment to delivery interval and a sig-
nificantly longer ROM to delivery time than
the non-infected neonates; whereas, there was
no difference between the infected and non-
infected neonates in the ambroxol group as
regards these three parameters (table VIII). All
deaths for infection occurred after the first
week of life. The type of infection and the
causal agents are listed in table IX.
The perinatal mortality of infants in the trial
was 9% (11/122) in the betamethasone group
and 8% (13/155) in the ambroxol group; the
28 day neonatal mortality was 12% (14/121) in
the betamethasone group and 8% (13/154) in
the ambroxol group; both differences were not
significant (table X).
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Table VII. Incidence of RDS in subgroups (infants).
Subgroups
Single delivery infants
Multiple delivery infants
Gestational age
< 30 weeks
31 -34 weeks
> 34 weeks
ROM to delivery time
^24 hours
25 -48 hours
> 48 hours
Treatment to delivery time
< 2 days
2- 7 day s
> 7 days
Sex
Female
Male
Betamethasone
(n = 86)
RDS Cases
20/68
7/18
10/12
13/49
4/25
14/49
O/ 5
13/32
5/16
13/35
9/35
15/35
12/51
(%)
29
39
83
26
16
28
41
31
37
26
43
23
Ambroxol
(n = 83)
RDS Cases
11/69
0/14
21 1
6/51
3/25
9/60
O/ 5
2/18
3/24
1/19
7/40
5/45
6/38
(%)
16
0
29
12
12
15
11
12
5
17
11
16
P
<r Π 01s^. \J.\J i
< 0.05
<0.01
< 0.01
< 0.01
Table VIII. Characteristics of infected infants in treatment groups.
Treatment
Betamethasone group (n = 100)
Gestational age mean ± S. D. (days)
Treatment to delivery time mean + S. D. (days)
ROM >48 hours (%)
Ambroxol group (n = 140)
Gestational age mean + S. D. (days)
Treatment to delivery time mean + S. D. (days)
ROM >48 hours (%)
Infected infants
226.5 ± 23.6
13.5 + 19.5
38
243.5 + 17.5
20.3 ± 23.8
14
Non-infected
infants
246 + 23.7
33.6 + 26.7
15
249.2 ± 21.3
28.5 + 22.0
27
Ρ
< 0.005
< 0.005
<0.01
> 0.05
>0.05
>0.05
The mean gestational age at treatment and at
delivery, birth weight, Apgar score at 1 and 5
min were significantly lower in RDS than non-
RDS cases; however, mean ROM to delivery
time, percentage of male sex, incidence of cesar-
ean section and, particularly, use of beta-mime-
tics and mean treatment to delivery time, which
were thought to be more decisive than steroid
prevention [15] in reducing the incidence of
RDS, were not significantly different in RDS
and non-RDS cases (table XI).
The only short-term negative side effects seen
in the mothers, the fetuses, or the neonates
after ambroxol administration were nausea and
headache in about 10% of the mothers.
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Table IX. Neonatal infections.
Ambroxol group
Etiologic agent Type of infection
and day of onset
Betamethasone group
Etiologic agent
S. aureus
S. albus
S. albus
S. albus
S. albus
Candida sp.
Candida sp.
Candida sp.
E. coli
E. coli
E. coli
Pseudomonas sp.
K. pneumoniae
Streptococcus spp.
Subcutaneous abscess (16th)
Subcutaneous abscesses (12th)*
Skin infection (26th)
Skin infection (10th)
Skin infection (13th)
Skin infection (14th)
Skin infection (15th)
Oral moniliasis (12th)
Oral moniliasis (17th)
Oral moniliasis (10th) °
Oral moniliasis (12th)
Oral moniliasis (14th)
Oral moniliasis (4th)
UTI(llth)
UTI (16th)
UTI(25th)°
UTI (4th)
UTI (26th)
UTI (12th)
UTI (10th)
UTI (27th)
UTI (20th)
Pneumonia (2nd)t
Pneumonia (5th)t
Pneumonia (llth)f
Pneumonia (2nd)
Sepsis (12th)t
Sepsis (22nd)t
Conjunctivitis (2nd)*
Conjunctivitis (18th)
Otitis media (16th)
Omphalitis (7th)
Pharyngitis (3rd)
S. aureus
S. albus
Candida sp.
Candida sp.
Candida sp.
Enterobacter
Proteus sp. + K. pneumoniae
Proteus sp.
E. coli
E. coli
K. pneumoniae
P. aeruginosa + E. coli
Pseudomonas sp.
Pseudomonas sp.
S. marcescens + P. aeruginosa
E. coli
P. aeruginosa
S. aureus
Proteus mirabilis + S. epidermidis
Morbidity rate = 9% (13/140)
Mortality rate = 0.7% (1/140)
Morbidity rate = 18% (18/100)
Mortality rate = 4% (4/100)
0
 Associated moniliasis and UTI (urinary tract infection)
* Associated conjunctivitis and subcutaneous abscesses
t Death
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Table XI. Factors influencing the development of RDS in our study population.
RDS
(n = 38)
Gestational age at delivery mean
Birth weight mean + S. D. (g)
± S. D. (days)
Gestational age at treatment mean + S.D. (days)
Treatment to delivery time mean
ROM to delivery time mean ± S
Use of betamimetics (%)
Cesarean section (%)
Male sex (%)
Placenta previa (%)
Apgar Γ (mean ± S.D.)
Apgar 5' (mean + S. D.)
Ambroxol treatment (%)
± S.D. (days)
. D. (hours)
222
1636
210
12
63
92
45
49
8
3.5
5.9
29
±
±
+
+
±
±
±
19
522
14
13
118
2.0
1.7
no-RDS
(n = 131)
233
2041
219.0
13
57
88
41
54
2
6.4
7.6
55
±
±
±
+
±
±
±
14
504
13
15
151
2.6
1.9
Ρ
< 0.005
< 0.001
< 0.005
> 0.05
>0.05
> 0.05
> 0.05
> 0.05
> 0.05
< 0.001
< 0.001
< 0.005
4 Discussion
The fact that none of the substances alleged
to increase surfactant production has yet been
accepted as a true alternative to steroids for
prevention of RDS is probably due to the diffi-
culty of correct clinical evaluation of their effi-
cacy. There are few other cases of drug efficacy
assessment in which the final effect — in the
present instance the lowering of the incidence
of RDS — can be influenced by such a large
number of different factors, of which those
currently known are:
1) gestational age at delivery, 2) birth weight,
3) gestational age at treatment, 4) treatment to
delivery time, 5) ROM to delivery time, 6) mode
of delivery, 7) neonatal condition at birth, 8)
sex of the newborn, 9) race of the newborn, 10)
use of beta-mimetic tocolytic agents, 11) twin
births, 12) fetal levels of PRL, T3 and T4, 13)
maternal smoking habits, 14) obstetric abnor-
malities including placenta previa, diabetes, Rh
immunization, hypertension.
If to these is added the difficulty of extrapolat-
ing animal model data to humans, it becomes
clear that any assessment of the efficacy of a
drug for RDS prevention must necessarily be
made by means of multiple randomized human
trials in which the principal interfering factors
are either excluded or homogeneously distrib-
uted among the groups studied. Such trials
should also be multicenter in nature, so as to
reduce the effect of variety in the quality of
prenatal care.
Our study has certain limitations, mainly due
to the fact that it is not blinded, even if non-
excluded interference factors were homogene-
ously distributed between the two groups.
Moreover, the percentage of low birth weight
infants was slightly, though not significantly,
higher in the betamethasone group, even if am-
broxol was significantly more effective than
betamethasone in infants born before the 31st
week.
Our incidence of RDS was rather high, com-
pared with that reported by others [1, 4, 7, 14]
and this was probably due to the fact that
we also considered all cases of mild RDS. We
consider noteworthy that in the ambroxol
group the incidence of RDS was significantly
lower in the severe cases taken alone where a
diagnostic error is less probable.
Thus, although clearly our results are by no
means conclusive, they suggest that ambroxol
is at least as effective as the steroids for preven-
tion of RDS and is effective also in cases ste-
roids are not, such as twin delivery, ROM more
than 48 hours prior to delivery, female sex.
Despite several experimental data demonstrat-
ing its effectiveness in stimulating surfactant
production, this drug had found only a some-
J. Perinat. Med. 15 (1987)
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what limited use for RDS prevention, mainly
because the usual dosage regimen (1 g/day for
5 days) is too long for cases of threatened
premature delivery, especially if there is con-
comitant ROM, as confirmed by the high per-
centage of cases that did not complete the total
dosage regimen in our trial too.
With a view to concluding clinical trials with
this substance, we had already successfully
checked that it significantly modified the palmi-
tic acid/stearic acid (P/S) ratio in amniotic fluid,
as compared with a placebo [9], using the more
time intensive dosage regimen in which 4 g were
administered in 36 hours. This same regimen
was available in this trial and gave better results
than the long dosage regimen, although the
difference was not significant.
The higher incidence of bacterial and micotic
infections in the infants of the betamethasone
group can be related to the findings of LAZZA-
RIN [6], showing a significant defect of PMNL
activity and a significant decrease of OKT4 +
cells (currently considered as T-helpers), in 10
preterm infants of the betamethasone group as
compared either with 10 preterm infants of the
ambroxol group or 10 preterm infants born to
non-treated mothers or 10 healthy term infants.
The damage to immunocompetent cell
functions might be the cause of the higher infec-
tion rate in steroid treated infants and warrants
great caution in the use of immunosuppressor
drugs in preterm newborns, which are already
susceptible to a high incidence of infectious
pathology, due to functional immaturity of cel-
lular immune responsiveness. Our findings sug-
gest that steroids might actually raise the risk
of infection in very low birth weight infants
and when ROM occurs more than 48 hours
before delivery.
In contrast, current knowledge suggests that
ambroxol lacks negative maternal, fetal and
neonatal side effects. This is a major advantage,
indicating this drug as a valid alternative to
steroids for prevention of RDS, if its efficacy
is confirmed by further studies, also in those
patients that were excluded in our trial, because
of the presence of a relative counterindication
to the use of steroids (hypertension, diabetes).
Since gestational age, birth weight and neonatal
well-being were the only decisive factors affect-
ing the development of RDS in our trial, it is
apparent that, together with maternal adminis-
tration of ambroxol, adequate tocolysis and
good prenatal care assure the most favorable
modes of delivery to preterm infants.
Summary
The results are reported of a multicenter randomized
study of the effectiveness of maternal administration of
betamethasone versus ambroxol, a substance of the
group of the benzylamines, for prevention of RDS in
preterm infants.
Women of 27 to 34 weeks gestation with threatened
premature delivery or planned premature delivery were
admitted to the trial. Between September 1981 and Nov-
ember 1984 a total of 288 randomized patients delivered
315 neonates. The incidence of RDS was assessed in 169
viable neonates born before the 37th week.
Of these 86 were born of 76 mothers treated with beta-
methasone and 83 of 76 mothers treated with ambroxol.
The overall incidence of RDS was significantly (P
< 0.05) higher in the betamethasone group (31%) than
the ambroxol group (13%). Ambroxol was significantly
more effective than betamethasone in twin births, in
infants born before the 31st week, when ROM to deliv-
ery time was more than 48 hours, when treatment to
delivery time was between 2 and 7 days and in female
infants.
The neonatal infection rate was significantly higher (P
< 0.05) in the group of betamethasone treated infants
(18% with four fatalities) than in the group of ambroxol
treated infants (9% with one fatality).
These results suggest that ambroxol may be a valid
alternative to steroids for prevention of RDS.
Keywords: Lung maturity, respiratory distress syndrome (RDS), surfactant.
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Zusammenfassung
Vergleich von Ambroxol und Betamethason zur Prevention
des RDS — eine multizentrische kontrollierte Studie
Es werden die Ergebnisse einer multizentrischen rando-
misierten Studie vorgestellt, in der die Wirksamkeit von
Betamethason bzw. Ambroxol, eine Substanz aus der
Gruppe der Benzylamine, zur Prävention eines RDS bei
Frühgeborenen miteinander verglichen wurde.
In die Studie aufgenommen wurden Frauen von der 27.
bis 34. Schwangerschaftswoche mit drohender Frühge-
burt bzw. geplanter vorzeitiger Entbindung. Zwischen
September 1981 und November 1984 wurde ein Kollek-
tiv von 288 randomisierten Patienten zusammengestellt,
die von insgesamt 315 Neugeborenen entbunden worden
waren. Bei 169 lebenden Kindern vor der 37. Woche
wurde ein RDS diagnostiziert. 86 dieser Kinder waren
aus der Gruppe von 76 Müttern, die mit Betamethason
behandelt worden waren, 83 aus der Gruppe von 76
Müttern, die Ambroxol erhalten hatten. In der Betame-
thason-Gruppe war die Inzidenz eines RDS signifikant
höher (p < 0.05) als in der Ambroxolgruppe (31% ver-
sus 13%).
Bei Zwillingsgeburten, bei Kindern vor der 31. Woche,
bei länger als 48 h zurückliegendem Blasensprung, bei
einem Zeitraum von 2 bis 7 Tagen von Behandlungsbe-
ginn bis zur Entbindung und bei weiblichen Neugebore-
nen war Ambroxol signifikant wirksamer als Betametha-
son.
Die neonatale Infektionsrate war in der Betamethason-
Gruppe signifikant höher als in der Ambroxol-Gruppe
(p < 0.05; 18% mit 4 Todesfällen versus 9% mit einem
Todesfall).
Unsere Ergebnisse zeigen, daß bei der Prävention des
RDS Ambroxol eine echte Alternative zu den Steroiden
sein kann.
Schlüsselwörter: Lungenreife, respiratorisches Distress-Syndrom (RDS), Surfactant.
Resume
Une alternative aux stero'ides pour la prevention du syn-
drome de detresse respiratoire (SDR): etude multicentri-
que avec groupe controle comparant ambroxol versus beta-
methasone
On rapporte les resultats d'une etude multicentrique
randomisee de l'efficacite de la prise maternelle de beta-
methasone versus ambroxol, substance du groupe des
benzylamines, dans la prevention du SDR chez les en-
fants prematures.
Sont entrees dans l'essai les femmes de 27 ä 34 semaines
de gestation avec une menace d'accouchement prema-
ture ou un accouchement premature programme. Entre
septembre 1981 et novembre 1984, 288 patierites rando-
misees, au total, ont donne naissance ä 315 nouveaux-
nes. On a estime l'incidence du SDR ä 169 nouveaux-
nes viables nes avant la 37eme semaine. Parmi ceux-ci
86 sont nes de 76 meres traitees par betamethasone et
83 de 76 meres traitees par ambroxol. L'incidence globale
du SDR a ete de fagon significative (p < 0,05) plus
elevee dans le groupe avec betamethasone (31%) que
dans le groupe avec ambroxol (13%).
L'ambroxol est plus efficace de fagon significative que
la betamethasone chez les jumeaux, chez les enfants
nes avant la 3lerne semaine, lorsque l'intervalle enfre
l'ouverture de l'oeuf et l'accouchement etait superieur ä
48 heures, lorsque le delai entre le traitement et l'accou-
chement etait compris entre 2 et 7 jours, et chez les
enfants de sexe feminin.
Le taux d'infections neonatales a ete de fagon significa-
tive (p < 0,05) plus eleve dans le groupe des enfants
traites par betamethasone (18% avec 4 deces) que dans
le groupe des enfants traites par ambroxol (9% avec l
seul deces).
Ces resultats suggerent que Pambroxol peut representer
une alternative valable aux stero'ides dans la prevention
du SDR.
Mots-cles: Maturite pulmonaire, surfactant, syndrome de detresse respiratoire (SDR).
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